BioSpace News Archive

Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for BAT1706, a proposed biosimilar to Avastin® (bevacizumab). Bio-Thera seeks commercial license for all approved indications of bevacizumab in China, advanced, metastatic or relapsed non-small cells lung cance

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission

The following quote is attributed to Frank Yiannas, Deputy Commissioner for Food Policy and Response: “The U.S. Food and Drug Administration, along with the Centers for Disease Control and Prevention and state and local partners, have likely linked a new outbreak of illnesses caused by Cyclospora to certain store brand ‘Gar

Innovent Biologics, Inc. announced that BYVASDA®, a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration of China for patients with advanced non-small cell lung cancer and metastatic colorectal cancer in China.

The testing and analysis services market is fairly fragmented with the presence of a number of small players offering services at competitive pricing, notes Transparency Market Research.

Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with PTEN loss tumors

The global respiratory disease testing market is extensively competitive and fragmented in nature because of large pool of players being present in the market, says an upcoming Transparency Market Research report.

The global ostomy drainage bags market is a highly competitive market with a large number of local and international players operating across the globe, states a new market research study by Transparency Market Research.

BeiGene, Ltd. announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application of BeiGene’s anti-PD-1 antibody tislelizumab in combination with chemotherapy for first-line treatment of patients with advanced non-squamous non-small cell lung cancer.

The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upswing in the demand for tapentadol worldwide.